Esmolol: a unique Beta-blocker in maintaining cardiovascular stability following neurosurgical procedures.

نویسندگان

  • Hamzeh Hosseinzadeh
  • Mahmood Eidy
  • Mehdi Ghaffarlou
  • Kamyar Ghabili
  • Samad Ej Golzari
چکیده

PURPOSE Patients with increased intracranial pressure (ICP) are prone to severe cardiac and or cerebral complications following emergence from general anesthesia and especially post-extubation phase. Administering beta blockers including esmolol is believed to be helpful in providing a stable hemodynamic at the end of the surgery and recovery stages and reducing recovery phase length. METHOD In a double-blind prospective randomized clinical trial, 60 adult patients with ASA (American Society of Anesthesiologist) class of I-II scheduled to undergo elective neurosurgery operations were randomly divided into two groups receiving esmolol (n=30) and placebo (n=30) as IV infusion within four minutes prior to extubation continued by an IV infusion for 10 minutes after extubation. RESULT There was a significant difference between two groups regarding the changes of systolic blood pressure and heart rate at all studied stages after extubation (P≤0.05). However, no significant difference existed between esmolol and control groups regarding recovery and extubation times emphasizing the fact that esmolol is of excellent early recovery and extubation profiles. CONCLUSION Esmolol is advised to be used in preventing hyperdynamic status throughout extubation phase without extending recovery phase length.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass

UNLABELLED The objective of this study was to investigate the effect of beta blocker on cardiac recovery and rhythm during cardiac surgeries. Sixty surgical rheumatic heart disease patients were received esmolol 1 mg/kg or the same volume of saline prior to removal of the aortic clamp. The incidence of cardiac automatic re-beat, ventricular fibrillation after reperfusion, the heart rate after s...

متن کامل

Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.

Esmolol is a new intravenous beta-adrenergic blocker with an ultrashort (nine-minute) elimination half-life, which has been studied predominantly for control of supraventricular tachycardia and management of certain types of hypertension. Clinical studies indicate that the efficacy of esmolol is equivalent to that of propranolol and verapamil for control of supraventricular tachycardia and to s...

متن کامل

Esmolol and beta-adrenergic blockade.

Tachycardia often presents difficult management problems in anesthesia. Because it increases myocardial oxygen demand so sharply, tachycardia can quickly place patients at risk of myocardial ischemia. It can occur for any number of reasons. Deepening the anesthetic, either with inhalation agent or opioids, will ablate increases in heart rate, but changes in heart rate are often transient and ch...

متن کامل

Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation.

Laryngoscopy and intubation cause an adrenergic response manifested by tachycardia and hypertension. Various pharmacological agents, including fentanyl, have been administered prior to induction in an attempt to attenuate the adrenergic response but they all have limitations. Esmolol, an ultrashort-acting cardioselective beta blocker, has been administered by infusion to successfully protect su...

متن کامل

90-day mortality of severe sepsis and septic shock is reduced by initiation of oral beta-blocker therapy and increased by discontinuation of a pre-existing beta-blocker treatment

Introduction A continuous infusion of the beta-blocker esmolol has recently been demonstrated to increase stroke volume without increasing norepinephrine dosage or impairing microcirculation in patients with septic shock [1]. In addition, a pre-existing oral therapy with beta-blockers was associated with a potential 28-day mortality survival benefit in septic patients [2]. The influence of a ne...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Advanced pharmaceutical bulletin

دوره 2 2  شماره 

صفحات  -

تاریخ انتشار 2012